| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate |
2022-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114763380-B |
| titleOfInvention |
Construct of nanobody S43 and its application |
| abstract |
The present invention provides a construct based on Nanobody S43 specifically binding to SARS-CoV-2 RBD (including multivalent Nanobody and Nanobody fusion protein), related products and applications thereof; the present invention is based on specifically binding SARS-CoV The construct of Nanobody S43 of ‑2RBD (including multivalent Nanobody and Nanobody fusion protein) can effectively inhibit SARS‑CoV‑2 infection and its mutant strain infection, and can be administered by nebulization, which can directly reach the lungs and take effect It is faster and has a long half-life, which provides a more effective therapeutic strategy for clinically preventing or treating infection of the new coronavirus and its mutant strains. |
| priorityDate |
2022-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |